Bavarian Nordic's MVA-BN® patent stands in European validity challenge
(Thomson Reuters ONE) -
Kvistgård, Denmark, October 5, 2010 - Bavarian Nordic A/S (OMX: BAVA) announced
today that the company successfully defended its core patent covering the MVA-
BN® technology despite aggressive attempts from competitors to revoke the patent
in Europe.
The patent was granted in December 2005 and after the nine month opposition
period in which any third party can file an opposition against any patent
granted in a European jurisdiction, seven companies opposed the patent. The
opposition proceeding has been pending at the European Patent Office for several
years.
After an oral hearing in the first instance the Opposition Division today
rendered its decision to uphold the patent with certain amended claims.
Bavarian Nordic's President & CEO, Anders Hedegaard commented: "We are very
pleased with the decision by the first instance to uphold our core patent, thus
confirming its uniqueness. We have substantially invested our resources to
develop our MVA BN® technology and our efforts have led to the creation of
valuable intellectual property, which we successfully have defended today."
Asger Aamund
Chairman of the Board
Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
About Bavarian Nordic
Bavarian Nordic is a leading industrial biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's clinical pipeline
targets cancer and infectious diseases, and includes seven development
programmes. Two programmes under preparation for Phase III: PROSTVAC(TM), a
therapeutic vaccine for advanced prostate cancer is being developed under a
collaboration agreement with the National Cancer Institute, and IMVAMUNE®, a
third-generation smallpox vaccine is being developed under a contract with the
US government.
Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.
For more information please visit www.bavarian-nordic.com
Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
[HUG#1449356]
201032uk:
http://hugin.info/100065/R/1449356/391285.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 05.10.2010 - 23:21 Uhr
Sprache: Deutsch
News-ID 44297
Anzahl Zeichen: 0
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 205 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic's MVA-BN® patent stands in European validity challenge"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
